详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Oncology, Linyi Cancer Hospital, Linyi, China. [2]Department of Cardiothoracic Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China. [3]Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China. [4]Department of Thoracic Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China. [5]Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China. [6]Department of Internal Medicine, Henan Cancer Hospital, Zhengzhou, China. [7]Department of Respiratory Diseases, Peking Union Medical College Hospital, Beijing, China. [8]Department of Internal Medicine-Oncology, Shandong Cancer Hospital, Jinan, China. [9]Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China. [10]Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. [11]Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China. [12]Department of Pulmonary Medicine, Lanzhou Military General Hospital, Lanzhou, China. [13]Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China. [14]Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, China. [15]Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. [16]Department of Respiratory Diseases, Tang Du Hospital, Xi'an, China. [17]First Department of Medical Oncology, Yunnan Cancer Hospital, Kunming, China. [18]Department of General Medicine, Capital Medical University, Beijing Chest Hospital, Beijing, China.

出处：

DOI：

ISSN：

摘要：

There is a lack of targeted therapeutic options for squamous cell lung cancer (SCC). Accelerated hypertension is an issue with many targeted therapies for lung cancer. This study aimed to analyze the efficacy of anlotinib, based on progression-free survival (PFS) and overall survival (OS) in patients with SCC, stratified by hypertension and Eastern Cooperative Oncology Group (ECOG) score.This was a post hoc analysis of a multicenter, double-blind, phase III ALTER0303 randomized controlled trial. Only patients with SCC were included. The occurrence of hypertension during the study period was defined according to CTCAE 4.03. OS and PFS were the primary and secondary endpoints, respectively. The patients were stratified according to hypertension and ECOG score, respectively.The median PFS in the patients who developed hypertension was longer than in those who did not (7.2 (95% CI: 3.5-11.0) versus 3.2 (95% CI: 1.2-5.3) months, p = 0.001; HR (95% CI), 0.4 (0.2-0.8)). In the ECOG 0 patients, the median PFS in the patients who developed hypertension versus those who did not was 5.6 vs. 1.8 months, respectively (Figure 2(d)). In the ECOG 1 patients, the median PFS in the patients who developed hypertension versus those who did not was 7.0 (95% CI: 3.0-11.0) vs. 4.8 (95% CI: 1.2-8.5) months (p = 0.043). No statistically significant differences were found in OS in the stratified analyses.The occurrence of hypertension might be a clinical indicator predicting the efficacy of third-line anlotinib treatment in patients with SCC.© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区肿瘤学 3 区呼吸系统

最新[2023]版：

大类 | 3 区医学

小类 | 4 区肿瘤学 4 区呼吸系统

第一作者：

第一作者机构： [1]Department of Oncology, Linyi Cancer Hospital, Linyi, China.

通讯作者：

通讯机构： [1]Department of Oncology, Linyi Cancer Hospital, Linyi, China. [*1]Department of Oncology, Linyi Cancer Hospital, No.6 Lingyuan East Street, Lanshan District, Linyi, 276001, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：